RNAi, miRNA & siRNA: A Focus on Nanotechnology & Delivery
/EINPresswire.com/ SMi present their annual RNAi, miRNA & siRNA: A Focus on Nanotechnology & Delivery Conference to be held on 11th &12th June 2012 in London.. This year's event will focus on the utility of nanotechnology to aid the delivery and development of novel therapeutics in the field of RNAi, miRNA and siRNA and senior industry executives will present attendees with in depth studies on targeted exosomes, structure-activity relationships and antisense technologies.
Key Benefits of Attending:
• Learn about and consider solutions to the issues within miRNA therapeutic identification and delivery strategies
• Evaluate Novartis and GSK's innovative strategies to ensure success in effective siRNA delivery
• Understand the latest advances in nanotechnology formulation and process engineering from Sanofi-Aventis
• Hear about antisense developments from RiboBio Pharmaceuticals and the University of Westminster
• Discuss current developments in novel RNAi therapeutics with experts form Santaris Pharma, Silence Therapeutics and Quark Pharmaceuticals
• Consider commercialisation and regulatory strategies in nanotechnology
• Network with key industry professionals and forge partnerships with key players in the field
HEAR KEY PRESENTATIONS FROM EXPERTS IN THE FIELD:
Structure-activity relationships of chitosan/siRNA nanoparticles in-vitro and vivo
Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research & Development, Novartis
Nanotech formulation and process engineering
Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis
Non-viral delivery of self-amplifying RNA vaccines
Andrew Geall, Platform Technology Leader, Novartis
Human mRNA and miRNA expression profiling following a major skin trauma
Paul Wilson, Senior Investigator, GlaxoSmithKline
RNAi and antisense technologies
Dmitry Samarsky, Executive Vice President, RiboBio Pharmaceuticals
For more information website: http://www.smi-online.co.uk/goto/pharma-nanotech26.asp
Alternatively contact Fateja Begum on +44 (0) 20 7827 6184 or email: fbegum@smi-online.co.uk
Quote "Medical News Today" to receive £100 discount!!
Key Benefits of Attending:
• Learn about and consider solutions to the issues within miRNA therapeutic identification and delivery strategies
• Evaluate Novartis and GSK's innovative strategies to ensure success in effective siRNA delivery
• Understand the latest advances in nanotechnology formulation and process engineering from Sanofi-Aventis
• Hear about antisense developments from RiboBio Pharmaceuticals and the University of Westminster
• Discuss current developments in novel RNAi therapeutics with experts form Santaris Pharma, Silence Therapeutics and Quark Pharmaceuticals
• Consider commercialisation and regulatory strategies in nanotechnology
• Network with key industry professionals and forge partnerships with key players in the field
HEAR KEY PRESENTATIONS FROM EXPERTS IN THE FIELD:
Structure-activity relationships of chitosan/siRNA nanoparticles in-vitro and vivo
Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research & Development, Novartis
Nanotech formulation and process engineering
Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis
Non-viral delivery of self-amplifying RNA vaccines
Andrew Geall, Platform Technology Leader, Novartis
Human mRNA and miRNA expression profiling following a major skin trauma
Paul Wilson, Senior Investigator, GlaxoSmithKline
RNAi and antisense technologies
Dmitry Samarsky, Executive Vice President, RiboBio Pharmaceuticals
For more information website: http://www.smi-online.co.uk/goto/pharma-nanotech26.asp
Alternatively contact Fateja Begum on +44 (0) 20 7827 6184 or email: fbegum@smi-online.co.uk
Quote "Medical News Today" to receive £100 discount!!
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.